This technology is an immunotherapy strategy to stop bone loss by selective osteoclast inhibition.
Bone diseases such as osteoporosis, Paget’s disease, osteolysis, osteoarthritis, and multiple myeloma may present with bone loss due to overactivation of osteoclasts. Current bone loss interventions, such as bisphosphonates, non-selectively inhibit the enzymatic activity of osteoclasts and may cause severe side effects such as osteonecrosis. There are currently no selective or highly targeted treatment options for bone loss due to osteoclast overactivation.
This technology identifies a target for highly selective osteoclast inhibition by blocking the receptor, programmed death one homolog (PD-1H), on osteoclasts. This disrupts the interaction between PD-1H and matrix metalloproteinase 13 (MMP-13), which is highly expressed on multiple myeloma plasma B cells. This technology may provide a therapeutic approach with higher specificity for downregulating osteoclast activity in bone disease and bone loss in multiple myeloma.
Patent Pending
IR CU20031
Licensing Contact: Jerry Kokoshka
